Reversal of ABC transporter-dependent multidrug resistance in cancer: A realistic option?

American Journal of Cancer

Volumn 5, Issue 5, 2006, Pages 285-297

  Stein, Ulrike ^a   Walther, Wolfgang ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; BIRICODAR; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FLUOROURACIL; FUMITREMORGIN C; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; IMATINIB; LANIQUIDAR; LY 475776; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; NSC 77037; ONT 093; PACLITAXEL; PREDNISONE; TARIQUIDAR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VERLUKAST; VINCRISTINE; VINDESINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIZATION; CLINICAL TRIAL; EWING SARCOMA; GENE EXPRESSION; HUMAN; HYPERTHERMIA; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; MYELOMA; NEUROBLASTOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TREATMENT FAILURE; TUMOR RESISTANCE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 33846884160     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605050-00001     Document Type: Review

References (159)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev 2002; 2: 48-58
2. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-92
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27
4. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34
5. Allikmets R, Gerrard B, Hutchinson A, et al. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 1996; 5: 1649-55
6. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51
7. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29
8. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98
9. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-66
10. Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol 2005; 400: 409-29
11. Tusnady GE, Sarkadi B, Simon I, et al. Membrane topology of human ABC proteins. FEBS Lett 2006; 580: 1017-22
12. Biemans-Oldehinkel E, Doeven MK, Poolman B. ABC transporter architecture and regulatory roles of accessory domains. FEBS Lett 2006; 580: 1023-35
13. Frelet A, Klein M. Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett 2006; 580: 1064-84
14. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62
15. Riordan JR, Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979; 254: 12701-5
16. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141: 956-62
17. Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987; 84: 3004-8
18. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-8
19. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-87
20. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265-9
21. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-59
22. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24
23. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003; 52: 759-66
24. Kohno K, Sato S, Takano H, et al. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989; 165: 1415-21
25. Chin KV, Tanaka S, Darlington G, et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990; 265: 221-6
26. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-6
27. Stein U, Walther W, Lemm M, et al. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int Cancer 1997; 72: 885-91
28. Stein U, Jurchott K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001; 276: 28562-9
29. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22: 7496-511
30. Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 1994; 30A: 1541-5
31. Stein U, Walther W, Shoemaker RH. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. J Cancer Res Clin Oncol 1996; 122: 275-82
32. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001; 1: 59-64
33. Hrycyna CA. Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance. Semin Cell Dev Biol 2001; 12: 247-56
34. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411-24
35. Di Nicolantonio F, Mercer SJ, Knight LA, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5: 78-94
36. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-5
37. Chevillard S, Pouillart P, Beldjord C, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996; 77: 292-300
38. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389-98
39. van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8
40. Riou GF, Zhou D, Ahomadegbe JC, et al. Expression of multidrug-resistance (MDR1) gene in normal epithelia and in invasive carcinomas of the uterine cervix. J Natl Cancer Inst 1990; 82: 1493-6
41. Abolhoda A, Wilson AE, Ross H, et al. Rapid activation of MDR1 expression in human metastatic sarcoma following in vivo exposure to doxorubicin. Clin Cancer Res 1999; 5: 3352-6
42. Stein U, Rau B, Wust P, et al. Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. Int J Cancer 1999; 80: 5-12
43. Stein U, Jurchott K, Schlafke M, et al. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 2002; 20: 3282-92
44. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 943: 1086-99
45. Chan HS, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 4: 689-704
46. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5
47. Stein U, Shoemaker RH, Schlag PM. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 1996; 32A: 86-92
48. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31
49. Chintamani C, Singh JP, Mittal MK, et al. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World J Surg Oncol 2005; 3: 61
50. Broxterman HJ, Sonneveld P, van Putten WJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000; 14: 1018-24
51. Ballatori N, Hammond CL, Cunningham JB, et al. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol 2005; 204: 238-55
52. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 2005; 15: 523-33
53. Cole SPC, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter MRP. BioEssays 1998; 20: 931-40
54. Loe DW, Deeley RG, Cole SP. Characterization of vincristin transport by the (M)r 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998; 58: 5130-6
55. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302
56. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006; 580 (4): 1103-11
57. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10
58. Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-61
59. Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1: 1301-10
60. Abbaszadegan MR, Futscher BW, Klimecki WT, et al. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994; 54: 4676-9
61. Filipits M, Suchomel RW, Dekan G, et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996; 2: 1231-7
62. Young LC, Campling BG, Voskoglou-Nomikos T, et al. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999; 5: 673-80
63. Oda Y, Dockhorn-Dworniczak B, Jurgens H, et al. Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol 1997; 123: 237-9
64. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-52
65. Nooter K, Brutel de la Riviere G, Look MP, et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997; 76: 486-93
66. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006; 24: 1546-53
67. Moureau-Zabotto L, Ricci S, Lefranc JP, et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006; 94: 473-80
68. Olson DP, Taylor BJ, La M, et al. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by teh Children's Oncology Group. Leuk Lymphoma 2005; 46: 681-91
69. Arts HJ, Katsaros D, de Vries EG, et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cacner Res 1999; 5: 2798-805
70. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086-99
71. Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-9
72. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998; 95: 15665-70
73. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8-13
74. Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91: 429-33
75. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63
76. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-41
77. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011-21
78. Stein U, Lage H, Jordan A, et al. Impact of BCRP/MXR, MRP1, and MDR1/P-glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer 2002; 97: 751-60
79. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 61: 6635-9
80. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 2002; 62: 2294-9
81. Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance associated protein BCRP/MXR/ABCP/ABCG2 in human tumors detected by the BXP-21 monoclonal antibody in paraffin-embedded material. Pathol 2002; 198: 213-9
82. Gillet JP, Efferth T, Steinbach D, et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004; 64: 8987-93
83. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129-37
84. Gyorffy B, Serra V, Jurchott K, et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005; 24: 7542-51
85. Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 2005; 5: 445-55
86. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237-62
87. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-65
88. Rothnie A, Storm J, McMahon R, et al. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett 2005; 579: 3984-90
89. Globisch C, Pajeva IK, Wiese M. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg Med Chem 2006; 14: 1588-98
90. Shepard RL, Cao J, Starling JJ, et al. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003; 103: 121-5
91. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-58
92. Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans 2005; 33: 241-5
93. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52: 609-27
94. Gekeler V, Ise W, Sanders KH, et al. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208: 345-52
95. Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002; 1: 417-25
96. Millward MJ, Cantwell BM, Munro NC, et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993; 67: 1031-5
97. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-20
98. Belpomme D, Gauthier S, Pujade-Lauraine E, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000; 11: 1471-6
99. Friedenberg WR, Tallman MS, Brodsky I, et al. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res 2004; 28: 813-9
100. Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006; 106: 830-8
101. van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106: 2646-54
102. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004; 22: 1078-86
103. Rago RP, Einstein Jr A, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2003; 51: 297-305
104. Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002; 86: 302-10
105. Toppmeyer D, Seidman AD, Pollak M, et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002; 8: 670-8
106. Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383-93
107. Sandler A, Gordon M, de Alwis DP, et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004; 10: 3265-72
108. Rubin EH, de Alwis DP, Pouliquen I, et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002; 8: 3710-7
109. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005; 104: 682-91
110. Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003; 9: 650-6
111. Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003; 9: 650-6
112. Stewart A, Steiner J, Mellows G, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000; 6: 4186-91
113. US National Institutes of Health [online]. Available from URL: http://www.ClinicalTrials.gov [Accessed 2006 May 16]
114. Le LH, Moore MJ, Siu LL, et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005; 56: 154-60
115. Fracasso PM, Goldstein LJ, de Alwis DP, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004; 10: 7220-8
116. Gerrard G, Payne E, Baker RJ, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004; 89: 782-90
117. Chen CC, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997; 3: 545-52
118. Peck RA, Hewett J, Harding MW, et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19: 3130-41
119. Chang CS, Yang SS, Yeh HZ, et al. Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression. Hepatogastroenterology 2004; 51: 211-4
120. Shiau YC, Tsai SC, Wang JJ, et al. Technetium-99m tetrofosmin chest imaging related to P-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Lung 2001; 179: 197-207
121. Bates SE, Chen C, Robey R, et al. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002; 243: 83-96
122. Wang H, Chen XP, Qiu FZ. Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1281-5
123. Yang CH, Huang CJ, Yang CS, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005; 65: 6943-9
124. Yeheskely-Hayon D, Regev R, Eytan GD, et al. The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. Leuk Res 2005; 29: 793-802
125. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006; 66: 4802-7
126. Tsuruo T, Hamada H, Sato S, et al. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989; 80: 627-31
127. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein- mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 1992; 89: 5824-8
128. Naito M, Tsuruo T. Monoclonal antibodies to P-glycoprotein: preparation and applications to basic and clinical research. Methods Enzymol 1998; 292: 258-65
129. Naito M, Tsuge H, Kuroko C, et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 1993; 85: 311-6
130. Watanabe T, Naito M, Kokubu N, et al. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 1997; 89: 512-8
131. FitzGerald DJ, Willingham MC, Cardarelli CO, et al. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci U S A 1987; 84: 4288-92
132. Efferth T, Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother 1992; 9: 11-9
133. Haus-Cohen M, Assaraf YG, Binyamin L, et al. Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope. Int J Cancer 2004; 109: 750-8
134. Tarasova NI, Seth R, Tarasov SG, et al. Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem 2005; 48: 3768-75
135. Pawlak-Roblin C, Tosi PF, Perrin L, et al. Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides. Eur J Cancer 2004; 40: 606-13
136. Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000; 97: 6775-9
137. Tanaka H, Ohshima N, Ikenoya M, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res 2003; 63: 6942-7
138. Zhou J, Liu M, Aneja R, et al. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006; 66: 445-52
139. Xu D, Ye D, Fisher M, et al. Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther 2002; 302: 963-71
140. Vasanthakumar G, Ahmed NK. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun 1989; 1: 225-32
141. Alahari SK, Dean NM, Fisher MH, et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 1996; 50: 808-19
142. Garcia-Chaumont C, Seksek O, Grzybowska J, et al. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000; 87: 255-77
143. Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 2003; 20: 351-9
144. Kang H, Fisher MH, Xu D, et al. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res 2004; 32: 4411-9
145. Matsumoto Y, Miyake K, Kunishio K, et al. Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 2004; 51: 194-201
146. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280: 1216-23
147. Morassutti C, Scaggiante B, Dapas B, et al. Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth. Biochimie 1999; 81: 1115-22
148. Sedelnikova OA, Panyutin IG, Luu AN, et al. Targeting the human mdr1 gene by 125I-labeled triplex-forming oligonucleotides. Antisense Nucleic Acid Drug Dev 2000; 10: 443-52
149. Kobayashi H, Takemura Y, Miyachi H. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum Cell 2001; 14: 172-84
150. Kobayashi H, Takemura Y, Wang FS, et al. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites. Int J Cancer 1999; 81: 944-50
151. Nagata J, Kijima H, Hatanaka H, et al. Reversal of drug resistance using hammer-head ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int J Oncol 2002; 21: 1021-6
152. Kowalski P, Stein U, Scheffer GL, et al. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002; 9: 579-86
153. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63: 1515-9
154. Li WT, Zhou GY, Song XR, et al. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 2005; 52: 219-24
155. Pichler A, Zelcer N, Prior JL, et al. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005; 11: 4487-94
156. Shi Z, Liang YJ, Chen ZS, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5: 39-47
157. Schinkel AH, Kemp S, Dolle M, et al. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993; 268: 7474-81
158. Sato W, Yusa K, Naito M, et al. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 1990; 173: 1252-7
159. Gupta KP, Ward NE, Gravitt KR, et al. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 1996; 271: 2102-11